16.40
price up icon2.05%   0.33
pre-market  Vorhandelsmarkt:  16.53   0.13   +0.79%
loading
Schlusskurs vom Vortag:
$16.07
Offen:
$16.18
24-Stunden-Volumen:
1.74M
Relative Volume:
0.96
Marktkapitalisierung:
$2.26B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-143.97M
KGV:
-11.80
EPS:
-1.39
Netto-Cashflow:
$9.60M
1W Leistung:
+8.39%
1M Leistung:
+13.73%
6M Leistung:
-37.74%
1J Leistung:
-28.54%
1-Tages-Spanne:
Value
$16.08
$16.88
1-Wochen-Bereich:
Value
$15.22
$17.19
52-Wochen-Spanne:
Value
$9.57
$30.41

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name
Firmenname
Arrowhead Pharmaceuticals Inc
Name
Telefon
626-696-4702
Name
Adresse
177 E COLORADO BLVD, PASADENA, CA
Name
Mitarbeiter
609
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
ARWR's Discussions on Twitter

Vergleichen Sie ARWR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ARWR
Arrowhead Pharmaceuticals Inc
16.40 2.12B 181.74M -143.97M 9.60M -1.39
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-06-05 Eingeleitet Goldman Neutral
2023-12-04 Eingeleitet BofA Securities Buy
2023-09-19 Eingeleitet Citigroup Neutral
2023-07-21 Eingeleitet TD Cowen Outperform
2023-05-12 Herabstufung SVB Securities Outperform → Market Perform
2023-04-26 Eingeleitet SMBC Nikko Outperform
2023-04-12 Hochstufung SVB Securities Market Perform → Outperform
2023-03-21 Eingeleitet Bernstein Mkt Perform
2022-09-09 Eingeleitet Morgan Stanley Equal-Weight
2022-05-11 Hochstufung Robert W. Baird Neutral → Outperform
2022-01-19 Fortgesetzt Goldman Buy
2021-08-06 Bestätigt Chardan Capital Markets Buy
2021-06-04 Fortgesetzt Robert W. Baird Neutral
2021-02-05 Bestätigt H.C. Wainwright Buy
2020-12-21 Herabstufung Robert W. Baird Outperform → Neutral
2020-12-16 Eingeleitet UBS Buy
2020-11-19 Eingeleitet Citigroup Buy
2020-05-13 Eingeleitet RBC Capital Mkts Outperform
2020-05-08 Hochstufung Oppenheimer Perform → Outperform
2020-04-15 Hochstufung Cantor Fitzgerald Neutral → Overweight
2020-03-24 Hochstufung SVB Leerink Underperform → Mkt Perform
2020-03-17 Eingeleitet Goldman Neutral
2020-01-21 Eingeleitet SVB Leerink Underperform
2019-12-13 Eingeleitet Oppenheimer Perform
2019-11-29 Bestätigt Chardan Capital Markets Buy
2019-11-27 Bestätigt B. Riley FBR Buy
2019-11-25 Hochstufung Robert W. Baird Neutral → Outperform
2019-10-24 Herabstufung Robert W. Baird Outperform → Neutral
2019-10-22 Bestätigt Chardan Capital Markets Buy
2019-10-03 Eingeleitet Robert W. Baird Outperform
2018-09-07 Hochstufung B. Riley FBR Neutral → Buy
2018-09-06 Bestätigt Chardan Capital Markets Buy
2018-08-08 Bestätigt Cantor Fitzgerald Overweight
2018-07-02 Bestätigt Chardan Capital Markets Buy
Alle ansehen

Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten

pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 31, 2025
pulisher
May 30, 2025

SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - BioSpace

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences | ARWR Stock News - GuruFocus

May 29, 2025
pulisher
May 24, 2025

Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com

May 24, 2025
pulisher
May 20, 2025

Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

May 19, 2025
pulisher
May 18, 2025

Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 18, 2025

B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World

May 18, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

May 17, 2025
pulisher
May 17, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - Defense World

May 17, 2025
pulisher
May 16, 2025

ARWR: Multiple Value Drivers for Long-Term Growth - Research Tree

May 16, 2025
pulisher
May 16, 2025

Q3 Earnings Forecast for ARWR Issued By Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 16, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

May 16, 2025
pulisher
May 15, 2025

Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks

May 15, 2025
pulisher
May 15, 2025

Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum - MSN

May 15, 2025
pulisher
May 15, 2025

ARWR July 18th Options Begin Trading - Nasdaq

May 15, 2025
pulisher
May 15, 2025

ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Citigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $17.00 - Defense World

May 15, 2025
pulisher
May 14, 2025

UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings Beat - Defense World

May 14, 2025
pulisher
May 14, 2025

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus

May 14, 2025
pulisher
May 13, 2025

RBC cuts Arrowhead Pharma target to $40; keeps Outperform By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highl - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus

May 13, 2025
pulisher
May 12, 2025

Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals (ARWR) Prepares for Commercial Launch - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - BioSpace

May 12, 2025
pulisher
May 12, 2025

Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings: EPS of $2 - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals Swings to Fiscal Q2 Earnings; Shares Rise After Hours - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Arrowhead Pharmaceuticals soars 7% on massive earnings beat By Investing.com - Investing.com South Africa

May 12, 2025

Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Kapitalisierung:     |  Volumen (24h):